FINWIRES · TerminalLIVE
FINWIRES

KRX:068270

5 stories mentioning KRX:068270Updated just now

Every FINWIRES story that references KRX:068270, newest first.

Asia

Celltrion's EU Clinical Trial Nod for Crohn's Disease Drug Lapses

Celltrion's (KRX:068270) said approval for Part 1 of its European Phase 3 clinical trial application for Remsima (CT-P13 SC) in pediatric patients with Crohn's Disease has lapsed, according to a Friday filing with the Korea Exchange.The approval lapsed on June 18 after the South Korean biopharmaceutical company opted not to submit Part 2 of the application, citing changes to its clinical development strategy.Under the European Union Clinical Trials Regulation, approval for Part 1 automatically lapses if Part 2 is not filed within two years.Celltrion said plans and timelines for the study will be determined following consultations with regulators on the trial design.Shares of Celltrion fell over 2% in recent trade.

KRX:068270
Asia

Celltrion's EU Clinical Trial Nod for Ulcerative Colitis Drug Lapses

Celltrion (KRX:068270) said approval for Part 1 of its European Phase 3 clinical trial application for Remsima (CT-P13 SC) in pediatric patients with moderately to severely active ulcerative colitis has lapsed, according to a Friday filing with the Korea Exchange.The approval lapsed on June 18 after the South Korean biopharmaceutical company opted not to submit Part 2 of the application, citing changes to its clinical development strategy.Under the European Union Clinical Trials Regulation, approval for Part 1 automatically lapses if Part 2 is not filed within two years.Celltrion said plans and timelines for the study will be determined following consultations with regulators on the trial design.Shares of Celltrion fell over 2% in recent trade.

KRX:068270
Asia

Market Chatter: Celltrion Workers Form Labor Union

Workers at bio firm Celltrion (KRX:068270) have formed a labor union, with a view to have compensation transparency, according to a report by the Yonhap News Agency on Monday.The union aims to increase staffing and improve employee benefits, the report said.Meanwhile, the company plans to respond to the formation in "good faith", the report added.(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)

KRX:068270
Asia

Celltrion's Net Attributable Income Jumps 219% in Q1

Celltrion (KRX:068270) posted first-quarter net income attributable to shareholders of 346.1 billion won, up 219% from 108.7 billion won a year earlier, according to a Wednesday filing with the Korea Exchange.The South Korean biopharmaceutical company's sales rose 36% year over year to 1.144 trillion won from 841.9 billion won.Shares of Celltrion fell nearly 2% at market close.

KRX:068270
Asia

Celltrion to Retire KRW100 Billion Worth of Treasury Shares

South Korean biopharmaceutical company Celltrion (KRX:068270) plans to retire 488,983 treasury shares, valued at 100 billion won, according to a Wednesday filing with the Korea Exchange.The shares will be retired on May 21 at a par value of 1,000 won apiece.

KRX:068270

Track with the FINWIRES app suite

FolioX
FolioX
Track KRX:068270 in your portfolio
WheelAI
WheelAI
Analyze KRX:068270 options with the wheel strategy
StockInsider
StockInsider
See market sentiment on KRX:068270